ICCM News and Press, IceCure Medical Ltd. From 02/26/24

Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer PR Newswire Independent study in women deemed inoperable for breast cancer reports median tumor reduction of 100% at 6 and 12 months following cryoablation ...

IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan PR Newswire CAESAREA, Israel , Feb. 15, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minim...

2024-01-31 08:28:40 ET Losers: Remark Holdings ( MARK ) -46% . Nuvve Holding Corp ( NVVE ) -30% . New York Community Bancorp NYCB -26% after Q4 earnings release . Mmtec ( MTC ) -18% . Extreme Networks EXTR -4% after Q2 earnings rel...

2024-01-30 17:23:08 ET More on IceCure Medical IceCure Medical Ltd (ICCM) Q3 2023 Earnings Call Transcript IceCure shares rally 53% on ProSense kidney cancer study IceCure stock climbs 10% amid FDA appeal, earnings report Seeking Alpha’s Quant Rating o...

U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer PR Newswire IceCure to submit full 5-year dataset from entire ICE3 study population to the FDA this spring, ahead of p...

IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class PR Newswire IceCure exhibits and provides hands-on demonstrations at SIO 2024 Annual Meeting in Ca...

IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation PR Newswire ProSense® users speaking at the conference about cryoablation included ISVIR Presiden...

2024-01-12 16:08:39 ET More on IceCure Medical IceCure shares rally 53% on ProSense kidney cancer study IceCure stock climbs 10% amid FDA appeal, earnings report For further details see: IceCure Medical regains compliance with Nasdaq

CAESAREA, Israel, Jan. 12, 2024 (GLOBE NEWSWIRE) -- IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tum...

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results PR Newswire U.S. sales contin...